Vasculitis and Giant Cell Arteritis News

DESTIN, Fla. — IgG4-related disease may be regarded as this century’s “greatest mimicker,” but upcoming therapies and discoveries are reasons for excitement, according to a speaker at the 2023 Congress of Clinical Rheumatology-East.

DESTIN, Fla. — Despite advances in biologic therapies, “excess steroid use” remains a mainstay of treatment for patients with ANCA-associated vasculitis, according to a presenter at the 2023 Congress of Clinical Rheumatology-East.

The treatment target for patients with giant cell arteritis or polymyalgia rheumatica should be remission, with vascular damage prevention taking priority in patients with GCA, according to treat-to-target recommendations from EULAR.

Weekly tocilizumab 162 mg is recommended for giant cell arteritis in new or relapsing cases, alongside glucocorticoids that should eventually be tapered, according to an updated EULAR consensus statement on interleukin-6 inhibitors.

A new simulation model can predict a range of clinical outcomes for various therapy strategies in patients with ANCA-associated vasculitis, according to data published in Arthritis Care & Research.